Tangji Medical raises US$13.8M+ Series C+ for gastric bypass stent system
What's the deal? Tangi Medical, a Chinese medtech company developing non-surgical treatments for metabolic diseases, has closed a C+ funding round of over US$13.8M (roughly $14M). The round was led by Nantong Investment Management, with several other institutional investors participating.
The funds will go toward clinical translation and commercialisation of the company's core product pipeline, particularly its "gastric bypass stent system" — a minimally invasive implant designed to treat obesity without traditional bariatric surgery.
Why now? China is facing a surging obesity crisis. The country now has more than 200 million clinically overweight or obese adults, driving massive demand for effective treatments beyond diet drugs and invasive surgery.
Tangi Medical's gastric bypass stent has already entered China's National Medical Products Administration (NMPA) special review pathway for innovative medical devices — a fast-track designation that signals regulatory momentum. The company says it is the first in China to conduct clinical research on this type of implant procedure for obesity treatment.
What could go wrong? Medtech companies face long, expensive roads from clinical trials to market approval, even on fast-track pathways. The device will need to demonstrate clear safety and efficacy advantages over GLP-1 weight-loss drugs like semaglutide, which are rapidly gaining popularity in China and globally.
Reimbursement is another hurdle. Novel medical devices in China often struggle to secure insurance coverage, which could limit patient adoption even after regulatory approval.
The signal: This deal reflects growing investor appetite for hardware-based obesity solutions that complement — or compete with — the booming weight-loss drug market. As GLP-1 medications dominate headlines, device makers are betting that implantable, procedure-based alternatives can carve out a significant niche, especially for patients who want durable results without lifelong drug regimens.
Source: itjuzi.com
